阿尼製藥 ANIP 深 滬
已收盤 02-06 16:00:00 美东时间
81.84
+0.340
+0.42%
華盛通- 最 高82.42
- 今 開82.42
- 成交量 30.18万股
- 最 低 80.57
- 昨 收 81.50
- 總市值 18.39亿
- 52周最高 99.50
- 市盈率 靜 --
- 換手率 1.34%
- 52周最低 54.10
- 委 比 -81.72%
- 總股本 2246.90万
- 歷史最高 99.50
- 量 比 0.87
- 振 幅 2.27%
- 歷史最低 0.80
- 每 手 1
- 風險率 12.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Guggenheim Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)
Guggenheim analyst Vamil Divan reiterated a Buy rating on ANI Pharmaceuticals y...
01-16 20:26
ANI Pharmaceuticals Sees FY2026 Sales $1.055B-$1.115B vs $955.053M Est
ANI Pharmaceuticals (NASDAQ:ANIP) sees FY2026 sales of $1.055 billion-$1.115 billion vs $955.053 million analyst estimate.
01-12 20:00
ANI Pharma Expects FY25 Total Net Revenues Of $854M-$873M And Adj. Non-GAAP EPS Of $7.37-$7.64
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37
01-12 19:58
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
ANI Pharmaceuticals reported strong financial performance in 2025, with total net revenues exceeding $854 million and adjusted non-GAAP EBITDA exceeding $221 million. Cortrophin Gel net revenues reached $347.8 million, up 76% year-over-year, while ILUVIEN and YUTIQ combined net revenues were $74.9 million. For 2026, the company expects total net revenues of $1.055 billion to $1.115 billion, with Cortrophin Gel contributing $540 million to $575 mi...
01-12 11:50
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The live and archived webcast will be available on the company’s website under the Investors section. ANI is a biopharmaceutical company focused on developing innovative therapeutics in rare diseases, generics, and branded products.
01-06 21:15
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $100
Barclays analyst Glen Santangelo initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Overweight rating and announces Price Target of $100.
2025-12-09 23:27
ANI Pharma Elects Thomas Haughey As Chairman Of The Board, Succeeding Patrick Walsh
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that its Chairman, Patrick D. Walsh, will retire from the Company's Board of Directors after a distinguished tenure of service. His
2025-12-01 19:53
ANI Pharmaceuticals Announces Board Transition
Patrick D. Walsh has retired as Chairman of ANI Pharmaceuticals, Inc., effective after the 2026 Annual Meeting. Thomas J. Haughey, a Board member since 2018, has been elected as the new Chairman. Walsh expressed pride in ANI's growth and confidence in the team's future. Haughey emphasized his commitment to supporting patients and delivering profitable growth. Jeanne Thoma will replace Haughey as Chair of the Audit and Finance Committee. This lead...
2025-12-01 11:50
